Role of p53 family in cancer

Publications

Tournillon, A., Lopez, I., Malbert-Colas, L., Findakly, S., Naski, N., Olivares-Illana, V., Karakostis, K., Vojtesek, B., Nylander, K., Fahraeus, R. p53 binds the mdmx mRNA and controls its translation. Oncogene 2016 [Epub ahead of print] (IF2015: 7,932)

Turnquist, C., Horikawa, I., Foran, E., Major, E.O., Vojtesek, B., Lane, D.P., Lu, X., Harris, B.T., Harris, C.C. p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration.Cell Death Differ 2016. [Epub ahead of print] (IF2014: 8,184)

Orzol, P., Nekulova, M., Holcakova, J., Muller, P., Vojtesek, B., Coates, P.J. ΔNp63 regulates cell proliferation, differentiation, adhesion, and migration in the BL2 subtype of basal-like breast cancer. Tumor Biol 2016. [Epub ahead of print] (IF2014: 3,611)

López, I., Tournillon, A.S, Fåhraeus, R. p53-mediated control of gene expression via mRNA translation during Endoplasmic Reticulum stress. Cell Cycle 2015;14(21):3373-3378. (IF2014: 4,565)

Mikulenkova, E., Neradil, J., Zitterbart, K., Sterba, J., Veselska, R. Overexpression of the ∆Np73 isoform is associated with centrosome amplification in brain tumor cell lines. Tumour Biol2015;36(10):7483-7491. (IF2014: 3,611)

Dvořáková, P., Nekulová, M., Holčáková, J., Vojtěšek, B., Hernychová, L. Analýza změn fosfoproteomu nádorové buněčné linie MDA- MB- 468 v odpovědi na expresi izoforem p63 pomocí hmotnostní spektrometrie. Klin Onkol 2015;28(Suppl 2):2S11-2S19. (bez IF)

Cefalu, S., Lena, A.M., Vojtesek, B., Musaro, A., Melino, G., Candi, E. TAp63gamma is required for the late stages of myogenesis. Cell Cycle 2015;14(6):894-901. (IF2014: 4,565)

Orzol, P., Holcakova, J., Nekulova, M., Nenutil, R., Vojtesek, B., Coates, P.J. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Histol Histopathol 2015;30:503-521. (IF2014: 2,096)

Fraser, J.A., Worrall, E.G., Lin Y., Landre, V., Pettersson, S., Blackburn, E., Walkinshaw, M., Muller, P., Vojtesek, B., Ball, K., Hupp, T.R. Phospohomimetic mutation of the N-terminal lid of MDM2 enhances the polyubiquitination of p53 through stimulation of E2-ubiquitin thioester hydrolysis.J Mol Biol 2015;427(8):1728-1747.(IF2014: 4,333)

Zhukova, N., Ramaswamy, V., Remke, M., Martin, D.C., Castelo-Branco, P., Zhang, C.H., Fraser, M., Tse, K., Poon, R., Shih, D., Baskin, B., Ray, P.N., Bouffet, E., Dirks, P., von Bueren, A.O., Pfaff, E., Korshunov, A., Jones, D., Northcott, P.A., Kool, M., Pugh, T.J., Pomeroy, S.L., Cho, Y., Pietsch, T., Gessi, M., Rutkowski, S., Bognár, L., Cho, B., Eberhart, C.G., Conter, C., Fouladi, M., French, P.J., Grajkowska, W.A., Gupta N, Hauser P, Jabado N, Vasiljevic A, Jung S, Kim S, Klekner A, Kumabe T, Lach, B., Leonard, J.R., Liau, L.M., Massimi, L., Pollack, I.F., Ra, Y., Rubin, J.B., Van Meir, E.G., Wang, K., Weiss, W.A., Zitterbart, K., Bristow, R.G., Alman, B., Hawkins, C.E., Malkin, D., Clifford, S.C., Pfister, S.M., Taylor, M.D., Tabori, U. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun 2014;2(1):174. (bez IF)

Horikawa, I., Fujita, K., Jenkins, L., Hiyoshi, Y., Mondal, A., Vojtesek, B., Lane, D., Appella, E., Harris, C. Autophagic degradation of the inhibitory p53 isoform Δ133p53α as a regulatory mechanism for p53-mediated senescence. Nat Commun 2014;5:4706. (IF2013: 10,742)

Malbert-Colas, L., Ponnuswamy, A., Olivares-Illana, V., Tournillon, A., Naski, N., Fåhraeus, R. HDMX folds the nascent p53 mRNA following activation by the ATM kinase. Mol Cell 2014;54(3):500-511. (IF2012: 15,280)

Bouchalova, P., Nenutil, R., Muller, P., Hrstka, R., Appleyard, M.V., Murray, K., Jordan, L.B., Purdie, C.A., Quinlan, P., Thompson, A.M., Vojtesek, B., Coates, P.J. Mutant p53 accumulation in human breast cancer is not an intrinsic property nor dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. J Pathol 2014;233(3):238–246. (IF2012: 7,585)

Dobes, P., Podhorec, J., Coufal, O., Jureckova, A., Petrakova, K., Vojtesek, B., Hrstka, R.Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. Oncol Rep 2014;32:1695-1702. (IF2013: 2,191)

Loljung, L., Coates, P.J., Nekulova, M., Laurell, G., Wahlgren, M., Wilms, T., Widlöf, M., Hansel, A., Nylander, K. High expression of p63 is correlated to poor prognosis in squamous cell carcinoma of the tongue. J Oral Pathol Med 2014;43(1):14-19. (IF2012: 2,055)

Kuricova, K., Pacal. L., Dvorakova, V., Kankova, K. Association of the Arg72Pro Polymorphism in p53 with Progression of Diabetic Nephropathy in T2DM Subjects. J Nephrol Ther 2014;4(2):153. (bez IF)

Nekulova, M., Holcakova, J., Vojtesek, B. Regulation of human reproduction by p53 members. Folia Mendeliana 2013;49(2):63-67. (Bez IF)

Mondal, A.M., Horikawa, I., Pine, S.R., Fujita, K., Morgan, K.M., Vera, E., Mazur, S.J., Appella, E., Vojtesek, B., Blasco, M.A., Lane, D.P., Harris, C.C.p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest 2013;123(12):5247-5257. (IF2012: 12,812)

Obacz, J., Pastorekova, S., Vojtesek, B., Hrstka, R. Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses. Mol Cancer 2013;12(1):93. (IF2012: 5,13)

Nekulova, M., Holcakova, J., Nenutil, R., Stratmann, R., Bouchalova, P., Müller, P., Moukova, L., Coates, P.J., Vojtesek, B. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry.Virchows Arch 2013:463:415–425. (IF2012: 2,676)

Brazdova, M., Navratilova, Tichy, V., Nemcova, K., Lexa, M., Hrstka, R., Pecinka, P., Adamik, M., Vojtesek, B., Palecek, E., Deppert, W., Fojta, M. Preferential Binding of Hot Spot Mutant p53 Proteins to Supercoiled DNAIn Vitro and in Cells. PLoS ONE 2013;8(3):e59567. (IF2012: 3,73)

Smardova, J., Liskova, K., Ravcuková, B., Kubiczkova, L., Sevcikova, S., Michalek, J., Svitakova, M., Vybiha,l V., Kren, L., Šmarda, J. High frequency of temperature-sensitive mutants of p53 in glioblastoma. Pathol Oncol Res 2013;19(3):421-428. (IF2012: 1,560)

Veselska, R., Neradil, J., Nekulova, M., Dobrucka, L., Vojtesek, B., Sterba, J., Zitterbart, K.Intracellular distribution of the DeltaNp73 protein isoform in medulloblastoma cells: a study with newly generated rabbit polyclonal antibodies. Histol Histopathol 2013;28(7):913-924. (IF2012: 2,281)

Logotheti, S., Pavlopoulou, A., Galtsidis, S., Vojtesek, B., Zoumpourlis, V. Functions, divergence and clinical value of TAp73 isoforms in cancer. Cancer Metastasis Rev 2013;32(3-4):511-534. (IF2012: 7,787)

Orzol, P., Nekulova, M., Vojtesek, B., Holcakova, J. p63 - an important player in epidermal and tumour development. Klin Onkol 2012;25(Suppl 2):2S11–2S15. (bez IF)

Ponnuswamy, A., Fahraeus, R. The regulation of p53 synthesis. Klin Onkol 2012; 25(Suppl 2): 2S32–2S37. (no IF)

 

Hupp, T.R., Hayward, R.L., Vojtesek, B. Strategies for p53 Reactivation in Human Sarcoma. Cancer Cell 2012;22(3):283-285. (IF2011: 26,566)

Molecular oncology for 21st century

Log In

Log In